The firm invests in middle market and mature companies in the health care, life sciences, cosmeceuticals, pharmaceuticals, enabling technologies and services, and diagnostic and medical devices sectors. It provides mezzanine and bridge financing and focuses on small molecules, proteins, antibodies, vaccines, phytopharmaceuticals, natural compounds, botanicals, antibiotics, and therapeutics in the pharmaceutical sector. In the diagnostic sector, it invests in genetic materials, biomarkers, pathological markers, genetic profiles, protein profiles, pharmacogenomics, food and environmental safety, genetically modified organism detection and trading, medical monitoring, diagnostic and analytical tools, and quality control. It also invests in enabling technologies and services such as novel packaging, process and production technologies, supply chain management, innovative materials and resources, and delivery systems for active compounds. The firm operates globally out of four offices and has $1.5 billion committed capital.